Zonsen PepLib Biotech and Novartis sign worldwide license agreement regarding radioligand therapy asset
On January 12, 2026, Zonsen PepLib Biotech Inc. (“PepLib”) announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset.
The asset has been developed internally by PepLib to date. Through this transaction, Novartis, an experienced global leader in RLTs, will advance the program to its next stage of development. The asset is expected to complement Novartis' existing RLT portfolio and to leverage the company's strong capabilities in the field to potentially bring a new targeted treatment option to patients worldwide.
Under the terms of the agreement, PepLib will receive an upfront payment of USD 50 million, with the potential to receive additional development, regulatory, and sales milestone payments, and is also eligible for tiered royalties on future global net sales.